Short-Term Changes in Serum PINP Predict Long-Term Changes in Trabecular Bone in the Rat Ovariectomy Model
- 25 January 2008
- journal article
- research article
- Published by Springer Nature in Calcified Tissue International
- Vol. 82 (2) , 155-161
Abstract
Serum procollagen I N-terminal propeptide (PINP) is a sensitive bone formation marker in humans. We have developed a nonradioactive immunoassay for rat PINP and studied PINP as a bone formation marker in the rat ovariectomy (OVX) model. Two OVX studies were performed with 3-month-old rats, both including measurement of PINP, C-terminal cross-linked telopeptide of type I collagen (CTX), and N-terminal mid-fragment of osteocalcin. A pilot 14-day study contained a sham-operated control group and an OVX group, and an extensive 8-week study contained a sham-operated control group and OVX groups receiving vehicle and 17β-estradiol (E2, 10 μg/kg/day s.c.). The bone markers were measured before the operation and at days 2, 4, 7, 10, and 14 in the pilot study and before the operations and at 2 and 8 weeks in the extensive study. Trabecular bone parameters were determined by peripheral quantitative computed tomography and histomorphometry from tibial metaphysis in the extensive study. The rat PINP immunoassay had the following characteristics: intra-assay coefficient of variation (CV) 2.8%, interassay CV 7.5%, dilution linearity 95%, and recovery 107%. PINP increased significantly during the first 2 weeks after OVX and returned to sham level at 8 weeks. E2 prevented the increase caused by OVX. Changes in PINP at 2 weeks correlated strongly with changes in CTX and osteocalcin at 2 weeks and with trabecular bone parameters at 8 weeks. As a conclusion, short-term changes in PINP predict long-term changes in trabecular bone parameters, suggesting that PINP is a reliable marker of bone formation in the rat OVX model.Keywords
This publication has 16 references indexed in Scilit:
- Biochemical markers in preclinical models of osteoporosisBiomarkers, 2007
- Effects of Teriparatide, Alendronate, or Both on Bone Turnover in Osteoporotic MenThe Journal of Clinical Endocrinology & Metabolism, 2006
- Anabolic Agents for OsteoporosisTreatments in Endocrinology, 2006
- Biochemical Markers of Bone Turnover in the Clinical Development of Drugs for Osteoporosis and Metastatic Bone DiseaseDrugs, 2006
- Serum TRACP 5b Is a Useful Marker for Monitoring Alendronate Treatment: Comparison With Other Markers of Bone TurnoverJournal of Bone and Mineral Research, 2005
- Early Changes in Biochemical Markers of Bone Formation Predict BMD Response to Teriparatide in Postmenopausal Women With OsteoporosisJournal of Bone and Mineral Research, 2005
- Biochemical Markers of Bone Metabolism and Prediction of Fracture in Elderly WomenJournal of Bone and Mineral Research, 2004
- Markers of Bone Turnover Predict Postmenopausal Forearm Bone Loss Over 4 Years: The OFELY StudyJournal of Bone and Mineral Research, 1999
- The ovariectomized rat model of postmenopausal bone lossBone and Mineral, 1991
- Bone changes after castration in rats. A model for osteoporosisActa Orthopaedica, 1986